83-OR: GLP-1RA Efficacy Doubled with Small Molecule Modulators of Pyruvate Kinase for Obesity Treatment
KIBBEY R, CARDONE R, RUZ-MALDONADO I, ZHAO X, BROWN S, FOSTER H, MERRINS M. 83-OR: GLP-1RA Efficacy Doubled with Small Molecule Modulators of Pyruvate Kinase for Obesity Treatment. Diabetes 2025, 74 DOI: 10.2337/db25-83-or.Peer-Reviewed Original ResearchGLP-1 RAsLean massCombo groupInsulin secretionOptimal treatment of obesityPreservation of lean massObesity treatmentTreatment groupsIslet healthCa2+ oscillationsCa2+ imagingFasting glucose levelsC57BL/6J male miceTreatment of obesityImproved insulin sensitivityGLP-1RAAUC glucoseOptimal treatmentDIO miceMale miceStudy endPlaceboGLP-1Body compositionInsulin sensitivityA Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts
Sosenko J, Cuthbertson D, Jacobsen L, Redondo M, Sims E, Ismail H, Herold K, Skyler J, Nathan B, Groups D. A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts. Diabetes Technology & Therapeutics 2025, 27: 179-186. PMID: 39757867, PMCID: PMC12084817, DOI: 10.1089/dia.2024.0422.Peer-Reviewed Original ResearchConceptsIndependent of insulin secretionArea under the curveAUC C-peptideAutoantibody-positive individualsC-peptideInsulin secretionAUC glucoseGlucose toleranceFirst-phase insulin responseDiabetes Prevention Trial-Type 1Type 1 diabetes progressionOral glucose tolerance test dataGlucose tolerance test dataPrediction of T1DImpaired glucose toleranceOral glucose toleranceType 1 diabetesDPT-1TrialNet PathwayIncreased glycemiaInsulin responseInverse correlationSecretionT1DLack of correlation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply